CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
Apple
AAPL
|
$9.08M |
| 2 |
Applied Materials
AMAT
|
$5.39M |
| 3 |
Arista Networks
ANET
|
$5.26M |
| 4 |
Amphenol
APH
|
$5.07M |
| 5 |
Alibaba
BABA
|
$4.29M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
UroGen Pharma
URGN
$896M
| $71.2K | 0.01% |
4,244
-1,659
| -28% | -$27.8K |
|
327
Olema Pharmaceuticals
OLMA
$432M
| $71.1K | 0.01% |
6,572
-3,990
| -38% | -$43.2K |
|
328
Phathom Pharmaceuticals
PHAT
$843M
| $70.8K | 0.01% |
6,877
-4,112
| -37% | -$42.4K |
|
329
Zymeworks
ZYME
$1.07B
| $70.7K | 0.01% |
8,306
-5,138
| -38% | -$43.7K |
|
330
Castle Biosciences
CSTL
$673M
| $70.6K | 0.01% |
3,242
-2,055
| -39% | -$44.7K |
|
331
Arbutus Biopharma
ABUS
$753M
| $68.5K | 0.01% |
22,171
-10,062
| -31% | -$31.1K |
|
332
Mineralys Therapeutics
MLYS
$1.94B
| $68.2K | 0.01% |
5,832
-2,099
| -26% | -$24.6K |
|
333
Regenxbio
RGNX
$498M
| $67.7K | 0.01% |
5,786
-2,733
| -32% | -$32K |
|
334
Humacyte
HUMA
$231M
| $67.2K | 0.01% |
13,990
-5,893
| -30% | -$28.3K |
|
335
Savara
SVRA
$591M
| $65.4K | 0.01% |
16,235
-9,800
| -38% | -$39.5K |
|
|
ITOS
336
DELISTED
iTeos Therapeutics
ITOS
| $65K | 0.01% |
4,378
-2,499
| -36% | -$37.1K |
|
337
Replimune Group
REPL
$460M
| $64.9K | 0.01% |
7,214
-4,594
| -39% | -$41.3K |
|
338
SIGA Technologies
SIGA
$617M
| $63.4K | 0.01% |
8,355
-5,305
| -39% | -$40.3K |
|
|
WBA
339
DELISTED
Walgreens Boots Alliance
WBA
| $62.7K | 0.01% |
5,187
+1,297
| +33% | +$15.7K |
|
340
Adaptive Biotechnologies
ADPT
$1.96B
| $62.7K | 0.01% |
17,314
-10,582
| -38% | -$38.3K |
|
|
THRD
341
DELISTED
Third Harmonic Bio
THRD
| $62.6K | 0.01% |
4,812
-2,972
| -38% | -$38.6K |
|
342
HUTCHMED
HCM
$2.62B
| $62.4K | 0.01% |
3,645
-2,288
| -39% | -$39.2K |
|
343
Y-mAbs Therapeutics
YMAB
$390M
| $62.3K | 0.01% |
5,156
-3,234
| -39% | -$39.1K |
|
|
CNTA
344
Centessa Pharmaceuticals
CNTA
$2.13B
| $61.5K | 0.01% |
6,808
-4,009
| -37% | -$36.2K |
|
345
Galapagos
GLPG
$2.06B
| $59.2K | 0.01% |
2,389
-1,380
| -37% | -$34.2K |
|
346
KalVista Pharmaceuticals
KALV
$713M
| $58.4K | 0.01% |
4,958
-3,066
| -38% | -$36.1K |
|
347
Allogene Therapeutics
ALLO
$249M
| $57.2K | 0.01% |
24,529
-7,819
| -24% | -$18.2K |
|
348
Oric Pharmaceuticals
ORIC
$1.03B
| $56K | 0.01% |
7,922
-5,000
| -39% | -$35.4K |
|
349
Ambarella
AMBA
$3.36B
| $54K | 0.01% |
1,000
| – | – |
|
350
EyePoint Pharmaceuticals
EYPT
$827M
| $53.3K | 0.01% |
6,121
-3,272
| -35% | -$28.5K |
|